Core Insights - Immunic Inc presented new data from the CALIPER Phase 2 trial at the ACTRIMS Forum, focusing on progressive multiple sclerosis (MS) and highlighting the efficacy of Vidofludimus calcium in reducing both acute and chronic inflammation [1][2][3] Group 1: CALIPER Trial Findings - The CALIPER trial showed a statistically significant reduction in slowly expanding lesions (SELs) for the 45mg dose of Vidofludimus calcium compared to placebo, indicating potential efficacy on chronic inflammation [7] - Vidofludimus calcium demonstrated a reducing effect on gadolinium-enhancing and T2 lesions, suggesting its impact on acute inflammation in MS [5] Group 2: EBV Reactivation Study - The trial provided clinical evidence of reduced Epstein-Barr virus (EBV) reactivation compared to placebo, which is significant given the role of EBV in MS progression [9] - T-cell receptor repertoire analysis indicated that under treatment with Vidofludimus calcium, EBV antigens dropped in ranking, suggesting fewer reactivations [10] Group 3: Future Outlook - Immunic is preparing for the readout of Phase 3 trials in relapsing MS, with results expected at the end of 2026 from two identical trials enrolling over 1,100 patients each, totaling more than 3,000 individuals [12]